Top Allergy Diagnostics Companies

Global Allergy Diagnostics Market size was valued at USD 4.80 Billion in 2024 and is poised to grow from USD 5.33 Billion in 2025 to USD 12.28 Billion by 2033, growing at a CAGR of 11% during the forecast period (2026–2033).

The competitive landscape of the global allergy diagnostics market is differentiated by the amalgamation of emerging companies and well-established players with ongoing strategic partnerships and innovations, reshaping the allergy diagnostics industry. Prominent players like Thermo Fisher Scientific, Quest Diagnostics, Eurofins Scientific, and Roche are focusing on in vitro diagnostics, comprehensive allergen testing competencies, and improved diagnostic tests and platforms for the detection of allergies. Furthermore, small enterprises and progressing companies are emphasizing niche products or modernized testing techniques like digital health solutions and molecular diagnostics. To boost rankings, established companies are heavily investing in R&D, engaging in collaborations, and increasing their geographic presence. 'Thermo Fisher Scientific Inc. (US)', 'Siemens Healthineers AG (Germany) ', 'Danaher (US) ', 'Canon Inc. (Minaris Medical America, Inc.) (Japan/US) ', 'Eurofins Scientific (Luxembourg) ', 'EUROIMMUN Medizinische Labordiagnostika AG (Revvity Inc.) (Germany/US) ', 'bioMérieux SA (France) ', 'Stallergenes Greer Ltd. (UK) ', 'HollisterStier Allergy (US) ', 'Omega Diagnostics Group PLC (UK) ', 'R-Biopharm AG (Germany) ', 'HYCOR Biomedical (US) ', 'Lincoln Diagnostics, Inc. (US) ', 'HOB Biotech Group Corp., Ltd. (China) ', 'Romer Labs Division Holding GmbH (Austria) ', 'AESKU.GROUP GmbH (Germany) ', 'Neogen Corporation (US) ', 'ALK-Abelló A/S (Denmark) ', 'Abbott Laboratories (US) ', 'Phadia (part of Thermo Fisher Scientific) (Sweden/US)'

The inclination towards personalized medicine is notably impacting allergy diagnostics. There is an increase demand for allergy tests that offer deep vision into personal sensitivities, enabling for more customized and personalized treatment decisions. Current research in detecting certain biomarkers associated with allergies improves the ability to create tailored treatment tactics, thus impacting the allergy diagnostics market growth. 

Mounting Use of Molecular Diagnostics: Molecular diagnostic techniques like allergen component testing and next-generation sequencing are gaining prominence. These techniques enable more accurate detection of certain allergens at molecular stage. This allergy diagnostics market trends improves precision of diagnostics, allowing better customized treatment plans depending on patient sensitivities. This ultimately results in better patient results. The commonly used molecular diagnostic methods include ELISA, PCR, and NHS.

Region-wise, North America dominated the global allergy diagnostics market in the previous years and is expected to lead over the forecast period owing to rising incidences of allergies, improved healthcare infrastructure, and education and strong awareness. The region reports a higher number of allergic conditions as compared to other regions. These comprise various food allergies, allergic rhinitis, asthma, and more, which demand on reliable diagnostic facilities a large scale. Also, North America holds a well-established healthcare infrastructure with easy access to superior diagnostic techniques and an expert workforce. This streamlines accuracy and time testing. Also, the public awareness regarding allergies is higher than other regions, resulting in proactive medical industry seeking high demand for testing. The key players profiled in the region include Thermo Fisher Scientific, Quest Diagnostics, Eurofins Scientific, Roche Diagnostics, ALK-Abelló, and more.